Can an 86-year-old female long-term-care resident taking duloxetine (Cymbalta) 30 mg daily and levetiracetam (Keppra) for seizures be started on valproic acid (Depakote) for mood?

Do Not Start Depakote for Mood in This Patient

Starting valproate (Depakote) for mood symptoms in this 86-year-old woman is not recommended due to significant safety concerns in the elderly, particularly the risk of cognitive impairment, hepatotoxicity, and lack of evidence supporting its use for mood in this population.

Key Safety Concerns with Valproate in the Elderly

Cognitive and Neurological Risks

Valproate carries substantial risk of dementia syndrome in elderly patients. A case report documented dementia syndrome in a 68-year-old woman after just one year of valproate use 1. At 86 years old, this patient is at particularly high risk for cognitive decline, which would worsen her quality of life beyond the current mood symptoms.

Hepatotoxicity Risk

The FDA label explicitly warns that serious or fatal hepatotoxicity can occur with valproate, preceded by non-specific symptoms including malaise, weakness, lethargy, and anorexia 2. While the highest risk is in children under 2 years, elderly patients with polypharmacy (she's already on duloxetine and levetiracetam) face increased vulnerability. The FDA mandates serum liver tests before therapy and at frequent intervals, especially during the first six months 2.

Drug Interaction Concerns

Valproate can significantly interact with her current medications. It acts as a metabolic inhibitor and can raise plasma concentrations of other drugs 3. The combination with duloxetine (Cymbalta) creates additional concern for CNS effects and potential serotonergic interactions.

Alternative Approaches for Mood Management

Optimize Current Antidepressant

The patient is on duloxetine 30 mg daily, which is a relatively low dose. Before adding another medication with significant risks:

• Consider increasing duloxetine to 60 mg daily (standard therapeutic dose for depression)
• Allow adequate time (4-6 weeks) to assess response at optimized dose

Address Underlying Causes

Per nursing home guidelines, behavioral and mood symptoms require comprehensive assessment 4:

• Evaluate for medical conditions: infections, dehydration, pain, delirium, fecal impaction
• Assess for psychosocial factors: actual or perceived abandonment, lack of social contact, environmental stressors
• Review medication side effects: levetiracetam itself can cause behavioral agitation and mood changes in 4-6% of patients 5, 6

Non-Pharmacological Interventions First

Guidelines strongly recommend non-pharmacological interventions as initial treatment for behavioral symptoms when there are no psychotic features and no immediate danger 4:

• Sensory therapy
• Activities therapy
• Social contact interventions
• Environmental modifications
• Behavioral therapy approaches

Consider Levetiracetam's Role

Levetiracetam (Keppra) can cause mood disturbances. Research shows it presents an intermediate risk for depression (approximately 4% prevalence) 5. Before adding valproate:

• Evaluate whether her current mood symptoms worsened after starting levetiracetam
• If seizures are well-controlled, consider discussing with neurology whether an alternative antiepileptic with better mood profile is appropriate

When Mood Stabilizers Are Truly Needed

If pharmacological mood stabilization becomes absolutely necessary after the above measures fail:

• Refer to psychiatry/geriatric psychiatry per guidelines: residents showing minimal improvement after 30 days of treatment should be referred to mental health professionals 4
• Consider atypical antipsychotics at low doses if psychotic features emerge (though these carry their own risks in elderly)
• Lamotrigine may be considered as it has a low risk for depression (<1%) and positive mood effects 5, though titration is slow

Critical Pitfalls to Avoid

1. Do not add valproate without exhausting safer options - the risk-benefit ratio is unfavorable in this elderly patient
2. Do not overlook levetiracetam as a potential contributor to mood symptoms
3. Do not skip comprehensive medical evaluation - "crying" and "abandonment issues" may reflect delirium, pain, or other treatable conditions
4. Do not use subtherapeutic doses of current medications - optimize duloxetine first

Monitoring if Valproate Were Considered (Not Recommended)

Should a specialist insist on valproate despite these concerns:

• Baseline and frequent liver function tests (especially first 6 months) 2
• Monitor for thrombocytopenia (3.85% discontinuation rate) 6
• Close cognitive monitoring for dementia syndrome 1
• Start at lowest possible dose with slow titration 3
• Plan for re-evaluation and discontinuation attempt within 6 months 4

The evidence strongly supports addressing this patient's mood symptoms through optimization of current therapy, comprehensive medical evaluation, non-pharmacological interventions, and psychiatric consultation rather than adding valproate with its significant risks in the elderly population.